GILD - Gilead Sciences, Inc.
| Previous Close | 75.59 |
| Open | 75.41 |
| Bid | 72.76 x 34100 |
| Ask | 72.93 x 1000 |
| Day's Range | 72.06 - 75.54 |
| 52 Week Range | 64.27 - 89.54 |
| Volume | 13,338,302 |
| Avg. Volume | 6,788,803 |
| Market Cap | 94.529B |
| Beta | 1.45 |
| PE Ratio (TTM) | 43.56 |
| EPS (TTM) | 1.67 |
| Earnings Date | Oct 24, 2018 - Oct 29, 2018 |
| Forward Dividend & Yield | 2.28 (2.93%) |
| Ex-Dividend Date | 2018-09-13 |
| 1y Target Est | 87.87 |
GuruFocus.com•yesterdayStanley Druckenmiller Bets on Facebook and Oil
Stanley Druckenmiller (Trades, Portfolio)'s Duquesne Capital spent purchased 19 new stocks in the second quarter, with his biggest purchase being of Facebook (FB), he revealed Wednesday. Warning! GuruFocus has detected 5 Warning Signs with SPLK.
Market Realist•yesterdayBiogen Expected to Report Robust Rise in Diluted EPS in 2018
In its Q2 2018 earnings conference call, Biogen (BIIB) updated its 2018 GAAP EPS guidance from the previously projected range of $22.20–$23.20 to $21.80–$22.40, which implies a YoY (year-over-year) rise of 83%–87%.
- Zacks•yesterday
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
Is (GILD) Outperforming Other Medical Stocks This Year?
- Market Realist•yesterday
Considering Allergan’s Q2 2018 Revenue Trend
As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.
Market Realist•yesterdayAnalyst Recommendations for Biogen and Its Peers in August
On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401, an investigational anti-amyloid-beta (or Aβ) protofibril antibody, in early Alzheimer’s disease (or AD) indication after 18 months of therapy. The patients also included those suffering from AD-related mild cognitive impairment as well as those with mild AD. The results from the Phase 2 trial seem to validate beta-amyloid as a potential target for treating Alzheimer’s disease.
Market Realist•2 days agoWhy Vertex Is Expected to Report Robust EPS Growth in 2018
How Is Vertex Pharmaceuticals Positioned in August? In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) reiterated its projection for non-GAAP combined selling, general, and administrative (or SG&A) and research and development (or R&D) expenses to come in in the range of $1.5 billion and $1.55 billion for fiscal 2018. In Q2 2018, the company reported non-GAAP combined R&D and SG&A expenses close to $388 million.
Market Realist•2 days agoVertex Pharmaceuticals Is Expected to See Robust Revenue Growth
In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) updated its revenue guidance for fiscal 2018 from the previously projected range of $2.65 billion–$2.8 billion to $2.9 billion–$3.0 billion. The midpoint of this guidance range would imply a 36% year-over-year (or YoY) rise in revenues in fiscal 2018. This expectation has mainly been driven by the solid adoption of Symdeko since its launch in US markets. The company has not assumed the impact of securing new reimbursement for its CF drugs in markets outside the US in its fiscal 2018 revenue guidance.
- Zacks•2 days ago
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years
- Motley Fool•2 days ago
Should Gilead Be Worried About This New Monthly HIV Medication?
The devil is in the undisclosed details.
Reuters•3 days agoLong-acting injection a shot in the arm for GSK's HIV business
A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.
Reuters•3 days agoLong-acting injection a shot in the arm for GSK's HIV business
A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.
- Reuters•4 days ago
Congo deploys experimental Ebola treatment as cases rise
GOMA, Democratic Republic of Congo/GENEVA, Aug 14 (Reuters) - D emocratic Republic of Congo has started using the experimental mAb114 Ebola treatment to counter the latest flare-up of the virus, health officials said on Tuesday, the first time it has been deployed against an active outbreak. Forty-two people are believed to have died from the haemorrhagic fever in Congo's tenth Ebola outbreak since it was discovered in the 1970s. In all, there have been 66 cases to date, including 39 confirmed and 27 probable, the health ministry said on Tuesday evening, an increase of nine confirmed cases since Monday.
- American City Business Journals•4 days ago
After five months on job, Gilead chief medical officer joins exodus
Dr. Andrew Cheng, appointed in March as chief medical officer of Gilead Sciences Inc., is leaving the company, joining an exodus of top-level executives from the Foster City-based drug developer. Cheng will "pursue another opportunity," Gilead (NASDAQ: GILD) said Tuesday while disclosing two promotions. Dr. Diana Brainard was promoted from vice president of clinical research, to senior vice president of HIV and emerging viral infections, and Gregg Alton, executive vice president of corporate and medical affairs, will become Gilead's first chief patient officer.
- Business Wire•4 days ago
Gilead Sciences Announces Executive Promotions
Gilead Sciences, Inc. (GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients. The company also announced that Diana Brainard, MD, has been promoted to Senior Vice President, HIV and Emerging Viral Infections, and that Andrew Cheng, MD, PhD, Chief Medical Officer, has decided to leave Gilead to pursue another opportunity.
- Zacks•5 days ago
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.
- Zacks•5 days ago
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
- Zacks•8 days ago
Biotech ETFs in Focus on String of Q2 Earnings Beat
Biotech ETFs draw attention post impressive Q2 results.
- Investopedia•8 days ago
Gilead Sciences Seen Rising 13% on Better Outlook
Gilead Sciences Inc. ( GILD) has risen by more than 18% since the start of May, and it looks likes shares may still be heading even higher. Analysts have been upping their earnings and revenue outlook for the biotech company since it reported blowout second-quarter results at the end of July, and now see the stock rising by nearly 13% based on the average price targets. Analysts have increased their average price on the stock to $87.40 since the company reported results, up from a prior target of $85.84.
- InvestorPlace•8 days ago
You Better Be Careful with Merck Stock, Especially at These Highs
Health care stocks including pharmaceutical giant Merck (NYSE:MRK) have gone on a nice run of late. Merk stock has gained over 20% just since early April, touching an all-time high this week. Q1 earnings that month seemed mixed, but the market reacted positively, and Merck raised guidance in the Q2 report late last month.
- Zacks•8 days ago
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Market Realist•9 days agoSangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.
- Market Realist•9 days ago
BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.
Market Realist•9 days agoHere’s How Exelixis Is Financially Positioned Now
Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.
- Zacks•9 days ago
PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.
- Motley Fool•9 days ago
Is Crispr Therapeutics Stock Grossly Overvalued?
Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?
